In this CME Outfitters livestream symposium, expert faculty will discuss the disease burden and impact of LGS on QoL for patients and caregivers, the utilization of diagnostic criteria and distinguishing features of both early- and late-onset LGS to achieve early and accurate diagnosis, and strategies to optimize LGS management across the lifespan of these patients.
Dr. Dixon-Salazar is a neuroscientist, geneticist, and patient advocate. Her desire to get her PhD was inspired by her daughter who developed Lennox-Gastaut Syndrome (LGS) at the age of 2. She completed her PhD and postdoctoral work at UC, San Diego, where she studied the mechanisms of brain development and synaptic plasticity, identified genetic causes of rare disorders in children, and researched precision therapeutics in stem cell and animal models of pediatric disease. During her research tenure, and after 16 years of watching daily, unrelenting seizures in her child, she uncovered the driver of her daughter’s illness and identified a novel precision therapy that improved her child’s life.
Dr. Dixon-Salazar left academia after 15 years in the lab with a drive to decrease the amount of time it would take for patients to benefit from lab discoveries in epilepsy precision medicine. She worked as Associate Research Director at CURE Epilepsy helping to move funding forward for novel translational research in genomic medicine for patients with severe forms of pediatric-onset epilepsy. She then transitioned to the Director of Research and Strategy at the Lennox-Gastaut Syndrome (LGS) Foundation where she worked directly with patients to access precision therapies and partnered with researchers, clinicians, regulators, policymakers, therapy developers, and other advocacy groups to build a sustainable precision medicine infrastructure for all patients with epilepsy. Currently, Dr. Dixon- Salazar serves as the Executive Director of the LGS Foundation, where the mission is to improve the lives of individuals impacted by LGS through advancing research, awareness, education, and family support
In this CME Outfitters livestream symposium, expert faculty will instruct learners on the role of pro-inflammatory cytokines in the pathogenesis of IBD. Learners will be guided on the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis and how to appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD. Faculty will model the development of individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent.
